January 22, 2021 Drug Utilization Review Board (DURB) Agenda
»
1. Call to order
1. Call to order
»
2. Approval of minutes from October 22 and October 23, 2020 (vote required)
2. Approval of minutes from October 22 and October 23, 2020 (vote required)
»
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Acne agents, oral b. Acne agents, topical c. Analgesics, narcotics long d. Analgesics, narcotics short e. Angiotensin modulator combinations f. Angiotensin modulators g. Antimigraine agents, other h. Antimigraine agents, triptans i. Antiparkinson agents j. Bladder relaxant preparations k. Glucagon agents l. H. pylori treatment m. Immunomodulators, atopic dermatitis n. Intranasal rhinitis agents o. Movement disorders p. Neuropathic pain q. Oncology, oral - Breast r. Oncology, oral - Hematologic s. Oncology, oral - Lung t. Oncology, oral - Other u. Oncology, oral - Prostate v. Oncology, oral - Renal cell w. Oncology, oral - Skin x. Phosphate binders y. Platelet aggregation inhibitors z. Progestins for cachexia aa. aa.Proton pump inhibitors ab. bb.Smoking cessation ac. cc.Stimulants and related agents
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Acne agents, oral b. Acne agents, topical
c. Analgesics, narcotics long
d. Analgesics, narcotics short
e. Angiotensin modulator combinations
f. Angiotensin modulators
g. Antimigraine agents, other
h. Antimigraine agents, triptans
i. Antiparkinson agents
j. Bladder relaxant preparations
k. Glucagon agents
l. H. pylori treatment
m. Immunomodulators, atopic dermatitis
n. Intranasal rhinitis agents
o. Movement disorders
p. Neuropathic pain
q. Oncology, oral - Breast
r. Oncology, oral - Hematologic
s. Oncology, oral - Lung
t. Oncology, oral - Other
u. Oncology, oral - Prostate
v. Oncology, oral - Renal cell
w. Oncology, oral - Skin
x. Phosphate binders
y. Platelet aggregation inhibitors
z. Progestins for cachexia
aa. aa.Proton pump inhibitors
ab. bb.Smoking cessation
ac. cc.Stimulants and related agents
»
4. Public comment on new drugs to be reviewed for the Medicaid PDL: » - a. Airduo Digihaler (inhalation) / Glucocorticoids, inhaled b. Armonair Digihaler (inhalation) / Glucocorticoids, inhaled c. Bafiertam Capsule Dr (oral) / Multiple sclerosis agents d. Breztri Aerosphere HFA AER AD (inhalation) / Glucocorticoids, inhaled e. Diclotrex Kit (topical) / Non-steroidal anti-inflammatory drugs (NSAIDs) f. Enbrel Vial (subcutaneous) / Cytokine and cell-adhesion molecule (CAM) antagonists g. Enspryng (subcutaneous) / Cytokine and CAM antagonists h. Hemady (oral) / Glucocorticoids, oral i. Kesimpta (subcutane) / Multiple sclerosis agents j. Semglee (subcutaneous) / Hypoglycemics, insulin and related agents
4. Public comment on new drugs to be reviewed for the Medicaid PDL: »
a. Airduo Digihaler (inhalation) / Glucocorticoids, inhaled b. Armonair Digihaler (inhalation) / Glucocorticoids, inhaled
c. Bafiertam Capsule Dr (oral) / Multiple sclerosis agents
d. Breztri Aerosphere HFA AER AD (inhalation) / Glucocorticoids, inhaled
e. Diclotrex Kit (topical) / Non-steroidal anti-inflammatory drugs (NSAIDs)
f. Enbrel Vial (subcutaneous) / Cytokine and cell-adhesion molecule (CAM) antagonists
g. Enspryng (subcutaneous) / Cytokine and CAM antagonists
h. Hemady (oral) / Glucocorticoids, oral
i. Kesimpta (subcutane) / Multiple sclerosis agents
j. Semglee (subcutaneous) / Hypoglycemics, insulin and related agents
»
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
»
6. Executive work session
6. Executive work session
»
1. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
1. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
»
2. Retrospective drug utilization review (DUR): Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Gabapentinoids Drug Utilization Evaluation (DUE) ii. Overutilization of antibiotics iii. Contraceptives DUE b. Report on recent retrospective DUR intervention outcomes: i. Pain management with opioids ii. Monitoring of psychotropic drugs in youth iii. Diabetes management c. Retrospective DUR proposals: (vote required) i. Benzodiazepine anxiolytics and controlled sedative/hypnotics DUE ii. Major depressive disorder (MDD) management
2. Retrospective drug utilization review (DUR): Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Gabapentinoids Drug Utilization Evaluation (DUE)
ii. Overutilization of antibiotics
iii. Contraceptives DUE
b. Report on recent retrospective DUR intervention outcomes:
i. Pain management with opioids
ii. Monitoring of psychotropic drugs in youth
iii. Diabetes management
c. Retrospective DUR proposals: (vote required)
i. Benzodiazepine anxiolytics and controlled sedative/hypnotics DUE
ii. Major depressive disorder (MDD) management
»
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) » - a. Apokyn and Kynmobi - new criteria (dopamine agonists) b. Evrysdi (oral solution) – new criteria c. Govovri and Osmolex - new criteria (Amantadine extended-release agents) d. Hemady (Dexamethsone) - new criteria
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) »
a. Apokyn and Kynmobi - new criteria (dopamine agonists) b. Evrysdi (oral solution) – new criteria
c. Govovri and Osmolex - new criteria (Amantadine extended-release agents)
d. Hemady (Dexamethsone) - new criteria
»
4. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) » - a. Angiotensin-converting enzyme inhibitors b. Angiotensin II receptor blockers c. Platelet aggregation inhibitors d. Proton pump inhibitors e. Sedative/hypnotics f. Serotonin 5-HT1B/1D receptor agonists
4. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) »
a. Angiotensin-converting enzyme inhibitors b. Angiotensin II receptor blockers
c. Platelet aggregation inhibitors
d. Proton pump inhibitors
e. Sedative/hypnotics
f. Serotonin 5-HT1B/1D receptor agonists
»
Items 5 & 6 » - 5. Next meeting date: April 23, 2021 6. Adjourn
Items 5 & 6 »
5. Next meeting date: April 23, 2021 6. Adjourn
